FHD-286 is a small molecule commercialized by Foghorn Therapeutics, with a leading Phase I program in Chronic Myelomonocytic Leukemia (CMML). According to Globaldata, it is involved in 3 clinical trials, of which 1 is ongoing, 1 is planned, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of FHD-286’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for FHD-286 is expected to reach an annual total of $68 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Foghorn Therapeutics Overview
Foghorn Therapeutics is a pharmaceutical company. The company discovers and develops novel drugs to treat cancer and other serious medical disorders. Its Gene Traffic Control Platform is a chromatin regulatory system that directs which genes our cells express and when, where and in what order. Foghorn Therapeutics products pipeline includes FHD-286 (BRM / BRG1), FHD-609 (BRD9), Selective BRM, and ARID1B. The company has developed a new approach of controlling gene expression, new insights, advanced six programs and created a discovery engine that yield’s additional targets in multiple types of cancers and other diseases. Foghorn Therapeutics is headquartered in Cambridge, Massachusetts, the US.
The company reported revenues of (US Dollars) US$19.2 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of US$1.3 million in FY2021. The operating loss of the company was US$117.1 million in FY2022, compared to an operating loss of US$102 million in FY2021. The net loss of the company was US$108.9 million in FY2022, compared to a net loss of US$101.3 million in FY2021. The company reported revenues of US$5.6 million for the second quarter ended June 2023, an increase of 5.5% over the previous quarter.
For a complete picture of FHD-286’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.